DK2575881T3 - Specifikke anti-CD160-antilegemer for behandling af øjensygdomme på grundlag af neoangiogenese - Google Patents
Specifikke anti-CD160-antilegemer for behandling af øjensygdomme på grundlag af neoangiogenese Download PDFInfo
- Publication number
- DK2575881T3 DK2575881T3 DK11728594.0T DK11728594T DK2575881T3 DK 2575881 T3 DK2575881 T3 DK 2575881T3 DK 11728594 T DK11728594 T DK 11728594T DK 2575881 T3 DK2575881 T3 DK 2575881T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- disease
- corneal
- scfv
- use according
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 39
- 208000030533 eye disease Diseases 0.000 title claims description 26
- 206010029113 Neovascularisation Diseases 0.000 title claims description 24
- 239000012634 fragment Substances 0.000 claims description 36
- 201000000159 corneal neovascularization Diseases 0.000 claims description 23
- 210000002889 endothelial cell Anatomy 0.000 claims description 23
- 208000002780 macular degeneration Diseases 0.000 claims description 23
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims description 20
- 206010038923 Retinopathy Diseases 0.000 claims description 15
- 230000002062 proliferating effect Effects 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 11
- 208000010412 Glaucoma Diseases 0.000 claims description 10
- 210000004408 hybridoma Anatomy 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 10
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 8
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 8
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 6
- 230000030833 cell death Effects 0.000 claims description 6
- 208000025464 Norrie disease Diseases 0.000 claims description 4
- 230000007613 environmental effect Effects 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 208000001491 myopia Diseases 0.000 claims description 4
- 230000004379 myopia Effects 0.000 claims description 4
- 230000002028 premature Effects 0.000 claims description 4
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 claims description 3
- 208000009043 Chemical Burns Diseases 0.000 claims description 3
- 208000021089 Coats disease Diseases 0.000 claims description 3
- 206010061788 Corneal infection Diseases 0.000 claims description 3
- 208000019878 Eales disease Diseases 0.000 claims description 3
- 206010015901 Exudative retinopathy Diseases 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 3
- 208000008709 Retinal Telangiectasis Diseases 0.000 claims description 3
- 201000005969 Uveal melanoma Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 201000007790 vitelliform macular dystrophy Diseases 0.000 claims description 3
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 claims description 3
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 3
- 206010065630 Iris neovascularisation Diseases 0.000 claims 1
- 201000008979 rubeosis iridis Diseases 0.000 claims 1
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 46
- 102100024263 CD160 antigen Human genes 0.000 description 42
- 241000699670 Mus sp. Species 0.000 description 42
- 206010028980 Neoplasm Diseases 0.000 description 40
- 229960000397 bevacizumab Drugs 0.000 description 35
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- 239000007924 injection Substances 0.000 description 26
- 238000002347 injection Methods 0.000 description 26
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 23
- 201000011510 cancer Diseases 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 229940120638 avastin Drugs 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- 210000001525 retina Anatomy 0.000 description 19
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 18
- 206010055665 Corneal neovascularisation Diseases 0.000 description 18
- 239000000427 antigen Substances 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 108091007433 antigens Proteins 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 229910052760 oxygen Inorganic materials 0.000 description 15
- 239000001301 oxygen Substances 0.000 description 15
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 14
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 14
- 230000033115 angiogenesis Effects 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 210000004087 cornea Anatomy 0.000 description 13
- 208000017442 Retinal disease Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 238000010172 mouse model Methods 0.000 description 11
- 208000007135 Retinal Neovascularization Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 9
- 241001529936 Murinae Species 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 9
- 230000002207 retinal effect Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 229910052743 krypton Inorganic materials 0.000 description 8
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 7
- 230000001772 anti-angiogenic effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 229960002143 fluorescein Drugs 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 229940076783 lucentis Drugs 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 6
- 238000011122 anti-angiogenic therapy Methods 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000004445 quantitative analysis Methods 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 229960003876 ranibizumab Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000005747 tumor angiogenesis Effects 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 4
- 108010052199 HLA-C Antigens Proteins 0.000 description 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 4
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000002583 angiography Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 102000054881 human CD160 Human genes 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000012771 intravital microscopy Methods 0.000 description 4
- 229960003299 ketamine Drugs 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001775 bruch membrane Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000003161 choroid Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 229960001802 phenylephrine Drugs 0.000 description 3
- 210000001747 pupil Anatomy 0.000 description 3
- 230000004276 retinal vascularization Effects 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 229960004791 tropicamide Drugs 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 3
- 229960001600 xylazine Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- KWHXMASXPBOSRE-JKIIOOKNSA-N (2z)-2-[(2r,3s,4s)-4-hydroxy-2-(3-hydroxypropyl)-3,4-dimethyl-3-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trienyl]cyclohexylidene]propanal Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC[C@@]1(C)[C@H](CCCO)\C(=C(\C)C=O)CC[C@]1(C)O KWHXMASXPBOSRE-JKIIOOKNSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000013128 Endothelin B Receptor Human genes 0.000 description 2
- 108010090557 Endothelin B Receptor Proteins 0.000 description 2
- 108010024164 HLA-G Antigens Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 101710150344 Protein Rev Proteins 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 101150001016 Rgs5 gene Proteins 0.000 description 2
- 241000710961 Semliki Forest virus Species 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000007614 Thrombospondin 1 Human genes 0.000 description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000000964 angiostatic effect Effects 0.000 description 2
- 230000003527 anti-angiogenesis Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000005775 apoptotic pathway Effects 0.000 description 2
- 235000004251 balanced diet Nutrition 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 230000002497 edematous effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000008497 endothelial barrier function Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000013534 fluorescein angiography Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- VWZKPZARAHDCMM-UHFFFAOYSA-N iridal Natural products CC(CC=C(C)C)C=CCCC(=CCCC1(C)C(CCCO)C(=C(C)/C=O)CCC1(C)O)C VWZKPZARAHDCMM-UHFFFAOYSA-N 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- PRGUDWLMFLCODA-UHFFFAOYSA-N oxybuprocaine hydrochloride Chemical compound [Cl-].CCCCOC1=CC(C(=O)OCC[NH+](CC)CC)=CC=C1N PRGUDWLMFLCODA-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000001116 retinal neuron Anatomy 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000007998 vessel formation Effects 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 240000000533 Capsicum pubescens Species 0.000 description 1
- 235000015855 Capsicum pubescens Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 102100035359 Cerebellar degeneration-related protein 2-like Human genes 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010719 Conjunctival haemorrhage Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000737792 Homo sapiens Cerebellar degeneration-related protein 2-like Proteins 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 description 1
- 241001397173 Kali <angiosperm> Species 0.000 description 1
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 238000013355 OIR mouse model Methods 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010055666 Retinal neovascularisation Diseases 0.000 description 1
- 206010039729 Scotoma Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000036866 Vitreoretinopathy Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 102000018568 alpha-Defensin Human genes 0.000 description 1
- 108050007802 alpha-defensin Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009552 doppler ultrasonography Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 229940020947 fluorescein sodium Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- -1 indium-ill Chemical compound 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000005025 intestinal intraepithelial lymphocyte Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000004303 low vision Effects 0.000 description 1
- 230000035168 lymphangiogenesis Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 229940105623 neo-synephrine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- QVGXLLKOCUKJST-OUBTZVSYSA-N oxygen-17 atom Chemical compound [17O] QVGXLLKOCUKJST-OUBTZVSYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000649 photocoagulation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004263 retinal angiogenesis Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 230000004233 retinal vasculature Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (10)
1. Anti-CD160-antilegeme og anti-VEGF-antilegeme som et kombineret præparat til samtidig, separat eller sekventiel anvendelse ved behandling og/eller forebyggelse af neovaskulære øjensygdomme.
2. Kombineret præparat til anvendelse ifølge krav 1, hvorved anti-CD160-antilegemet inducerer celledød af aktiverede, formerende endothelceller.
3. Kombineret præparat til anvendelse ifølge krav 1 eller krav 2, hvorved anti-CD160-antilegemet er en forbindelse, som er udvalgt fra monoklonale anti-CD160-antilegemer, konservative fragmenter, der er udvalgt fra en Fab, en Fab’, en F(ab)2, F(ab’)2 og dAB fra CL1-R2, og konservative afledede af CL1-R2, som er udvalgt fra scFv,(scFv)2, diabodierne, det multimere scFv, der er afledt fra CL1-R2 og fusioneret med et Fc-fragment, og antilegemer, som i det mindste indeholder to Fabs, der er bundet hoved-til-hale, hvorved CL1-R2 er et antilegeme, som kan opnås fra hybridomet, der er deponeret som CNCM I-3204.
4. Kombineret præparat til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvorved anti-CD160-antilegemet er en sammensætning, som er udvalgt fra monoklonale CL1-R2 antilegemer, deres konservative fragmenter, som er udvalgt fra en Fab, en Fab’, en F(ab)2, F(ab’)2 og dAB fra CL1-R2, og konservative afledede af CL1-R2, der er udvalgt fra scFv,(scFv)2, diabodierne, det multimere scFv, som er afledt fra CL1-R2 og fusioneret med et Fc-fragment, og antilegemer, der i det mindste indeholder to Fabs, som er bundet hoved-til-hale, hvorved CL1-R2 er et antilegeme, der kan opnås fra hybridomet, som er deponeret som CNCM I-3204.
5. Kombineret præparat til anvendelse ifølge et hvilket som helst af kravene 1 til 4, kendetegnet ved, at den neovaskulære øjensygdom er udvalgt fra: • alle former for korneale neovaskularisationer; • alle former for retinopatier; • Norrie-sygdom; • alle former for chroidale neovaskularisationer, retino-choroidale vaskulopa-tier, retrofoveolare choroidale neo-kar, som er relateret til myopia og Sorsby’s dystrofi; • uveale melanomer; og • rubeosis iridis og neovaskulært glaukom.
6. Kombineret præparat til anvendelse ifølge et hvilket som helst af kravene 1 til 5, kendetegnet ved, at den neovaskulære øjensygdom er udvalgt fra: • Neovaskulariseringer, der optræder som komplikationer ved korneale transplantater og/eller korneale infektioner og/eller korneale påvirkninger fra omverdenen (miljøpåvirkninger), og som er udvalgt fra patogene infektioner og kemiske forbrændinger; • diabetiske, iskæmiske og odematose retinopatier, for tidlig diabetisk re-tinopati, ikke-proliferative og proliferative former for retinopatier, zystoid makulaodem, alle former for aldersbetingede makula-degenereringer (AMD), alle vitelli-forme makula-degenereringer, inklusive Best-sygdommen; øje-anginom, såsom von Hippel-Lindau’s sygdom, Eale’s sygdom, Coats’ sygdom; • Norrie-sygdommen; • alle former for choroidale neovaskularisationer, retino-koroidale, polypo-idale vaskulopatier, retrofoveolare, choroidale neo-kar relateret til myopi og torsby-dystrofi; • choroidale melanomer og deres metastaser; og • rubiosis iridis og neovaskulært glaukom.
7. Kombineret præparat til anvendelse ifølge et hvilket som helst af kravene 1 til 6, med henblik på anvendelse ved behandling og/eller forebyggelse af neovaskulære øjensygdomme i et individ, som ikke reagerer på en anti-VEGF-behandling.
8. Kombineret præparat til anvendelse ifølge et hvilket som helst af kravene 1 til 7, med henblik på anvendelse ved behandling af aldersbetingede makula- degenerationer (AMD).
9. Kombineret præparat til anvendelse ifølge et hvilket som helst af kravene 3 til 8, kendetegnet ved, at sammensætningen er det monoklonale antilegeme CL1-R2, hvorved CL1-R2 er et antilegeme, som kan opnås fra hybridomet, der er deponeret som CNCM I-3204.
10. Kombineret præparat til anvendelse ifølge et hvilket som helst af kravene 3 til 8, kendetegnet ved, at det konservative derivat er en monovalent eller et multivalent scFV.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34927110P | 2010-05-28 | 2010-05-28 | |
| PCT/EP2011/058777 WO2011147984A1 (en) | 2010-05-28 | 2011-05-27 | Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2575881T3 true DK2575881T3 (da) | 2017-01-09 |
Family
ID=44276158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11728594.0T DK2575881T3 (da) | 2010-05-28 | 2011-05-27 | Specifikke anti-CD160-antilegemer for behandling af øjensygdomme på grundlag af neoangiogenese |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9045544B2 (da) |
| EP (1) | EP2575881B1 (da) |
| JP (1) | JP5990511B2 (da) |
| KR (1) | KR101847572B1 (da) |
| CN (2) | CN102892432A (da) |
| BR (1) | BR112012030318A2 (da) |
| CA (1) | CA2796312C (da) |
| DK (1) | DK2575881T3 (da) |
| ES (1) | ES2606627T3 (da) |
| PL (1) | PL2575881T3 (da) |
| WO (1) | WO2011147984A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10561707B2 (en) * | 2013-09-08 | 2020-02-18 | Technion Research And Development Foundation Ltd. | Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases |
| EP3145532A4 (en) * | 2014-05-02 | 2018-02-21 | Mayo Foundation for Medical Education and Research | Individualized treatment of eye disease |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| IL260323B2 (en) | 2015-12-30 | 2025-01-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| BR112019008345A8 (pt) * | 2016-10-25 | 2023-03-07 | Inst Nat Sante Rech Med | Anticorpos monoclonais ligados à isoforma transmembrana cd160 |
| FR3061716B1 (fr) | 2017-01-06 | 2019-05-17 | Elsalys Biotech | Nouveaux composes ciblant le cd160 humain |
| AU2018326835A1 (en) * | 2017-08-31 | 2020-03-26 | National University Of Singapore | Angio-3 for treatment of retinal angiogenic diseases |
| KR20200140817A (ko) | 2018-03-02 | 2020-12-16 | 코디악 사이언시스 인코포레이티드 | Il-6 항체 그리고 이의 융합 작제물 및 접합체 |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| US20230073132A1 (en) * | 2019-12-31 | 2023-03-09 | Medstar Health, Inc. | Anti-cd 160 binding molecules for treating diseases |
| CA3187272A1 (en) | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
| JP2024529381A (ja) | 2021-07-30 | 2024-08-06 | アフィメド ゲーエムベーハー | デュプレックスボディ |
| WO2024056861A1 (en) | 2022-09-15 | 2024-03-21 | Avidicure Ip B.V. | Multispecific antigen binding proteins for stimulating nk cells and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| CA2117477C (en) | 1992-12-11 | 2001-06-12 | Peter S. Mezes | Multivalent single chain antibodies |
| AU5253898A (en) | 1996-11-12 | 1998-06-03 | Dana-Farber Cancer Institute | Recombinant by55 and nucleic acids encoding same |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| FR2794977B1 (fr) * | 1999-06-18 | 2003-10-31 | Commissariat Energie Atomique | Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention |
| EP1626059A1 (en) * | 2004-08-09 | 2006-02-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Angiogenic and immunologic applications of anti-CD160 specific compounds obtainable from mAb CL1-R2 |
| JP2009525282A (ja) * | 2006-01-30 | 2009-07-09 | （オーエスアイ）アイテツク・インコーポレーテツド | 血管新生疾患の治療のための組み合わせ療法 |
| AR062239A1 (es) * | 2007-08-07 | 2008-10-22 | Civil De Estudios Superiores A | Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal |
-
2011
- 2011-05-27 CA CA2796312A patent/CA2796312C/en active Active
- 2011-05-27 PL PL11728594T patent/PL2575881T3/pl unknown
- 2011-05-27 BR BR112012030318A patent/BR112012030318A2/pt not_active Application Discontinuation
- 2011-05-27 US US13/697,699 patent/US9045544B2/en active Active
- 2011-05-27 KR KR1020127034345A patent/KR101847572B1/ko not_active Expired - Fee Related
- 2011-05-27 ES ES11728594.0T patent/ES2606627T3/es active Active
- 2011-05-27 EP EP11728594.0A patent/EP2575881B1/en active Active
- 2011-05-27 CN CN201180024138XA patent/CN102892432A/zh active Pending
- 2011-05-27 WO PCT/EP2011/058777 patent/WO2011147984A1/en active Application Filing
- 2011-05-27 CN CN201710912201.2A patent/CN107648605A/zh active Pending
- 2011-05-27 JP JP2013511702A patent/JP5990511B2/ja active Active
- 2011-05-27 DK DK11728594.0T patent/DK2575881T3/da active
-
2015
- 2015-06-02 US US14/728,253 patent/US10208124B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2575881A1 (en) | 2013-04-10 |
| CA2796312A1 (en) | 2011-12-01 |
| US9045544B2 (en) | 2015-06-02 |
| US20150344572A1 (en) | 2015-12-03 |
| ES2606627T8 (es) | 2017-06-09 |
| BR112012030318A2 (pt) | 2017-06-20 |
| CA2796312C (en) | 2020-11-03 |
| US10208124B2 (en) | 2019-02-19 |
| CN102892432A (zh) | 2013-01-23 |
| PL2575881T3 (pl) | 2018-06-29 |
| CN107648605A (zh) | 2018-02-02 |
| KR101847572B1 (ko) | 2018-05-24 |
| JP2013528607A (ja) | 2013-07-11 |
| WO2011147984A1 (en) | 2011-12-01 |
| ES2606627T3 (es) | 2017-03-24 |
| KR20130086548A (ko) | 2013-08-02 |
| EP2575881B1 (en) | 2016-09-14 |
| JP5990511B2 (ja) | 2016-09-14 |
| US20130122006A1 (en) | 2013-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2575881T3 (da) | Specifikke anti-CD160-antilegemer for behandling af øjensygdomme på grundlag af neoangiogenese | |
| CA2850824C (en) | Treatment of ocular disease | |
| RU2346701C2 (ru) | ХИМЕРНЫЕ И ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ ИНТЕГРИНА α5β1, КОТОРЫЕ МОДУЛИРУЮТ АНГИОГЕНЕЗ | |
| JP6760840B2 (ja) | アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用 | |
| TW200815468A (en) | Use of organic compounds | |
| TW202031287A (zh) | 利用抗fcrn抗體治療葛瑞夫茲氏眼病之方法 | |
| Chabot et al. | A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor | |
| US20080026033A1 (en) | CHIMERIC AND HUMANIZED ANTIBODIES TO alpha5beta1 INTEGRIN THAT MODULATE ANGIOGENESIS | |
| US20110110932A1 (en) | Combination treatment for ocular diseases | |
| WO2023001288A1 (zh) | 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 | |
| CN114728061A (zh) | 治疗糖尿病性视网膜病变的方法和组合物 | |
| JP7136468B2 (ja) | 抗セクレトグラニンｉｉｉ（ｓｃｇ３）抗体およびその使用 | |
| US11279755B2 (en) | Use of IL-20 antagonists for treating eye diseases |